Article Text

Unexpected outcome (positive or negative) including adverse drug reactions
Extended remission of metastatic epithelioid angiosarcoma of the heart with liposomal doxorubicin
  1. Carlos Marques Candeias1,
  2. Inês Luís2,
  3. Joana Ribeiro2,
  4. Luís Costa2,
  5. Luís Soares de Almeida3,
  6. Manuel Marques Gomes3,
  7. Luísa Barreto1,
  8. Luís Brito-Avô1,
  9. José Luís Ducla-Soares1
  1. 1Santa Maria Hospital, Medicine, Avenida Professor Egas Moniz, Lisbon, 1649-035, Portugal
  2. 2Santa Maria Hospital, Oncology, Avenida Professor Egas Moniz Lisbon, Lisbon, 1649-035, Portugal
  3. 3Santa Maria Hospital, Dermatology, Avenida Professor Egas Moniz, Lisbon, 1649-035, Portugal
  1. Correspondence to Carlos Marques Candeias, carlosmarquescandeias{at}gmail.com

Summary

Angiosarcoma is the most common primary malignant tumour of the heart. It is a rare and aggressive neoplasm that almost always has a short and fatal evolution. By the time it produces symptoms it has usually progressed to a mass causing haemodynamic compromise. Initial presentation with metastatic disease is unusual. We report the case of a 72-year-old man who presented with painful skin lesions on both hands. The skin biopsy was diagnosed as intravascular metastasis of epithelioid angiosarcoma. Body computed tomography scan disclosed a solid mass in the left atrium. The tumour was judged unresectable and the patient was treated with systemic chemotherapy, consisting of liposomal doxorubicin, which resulted in a complete clinical response. The patient remains free of disease after 48 months of follow-up. The excellent clinical evolution of our patient verifies that liposomal doxorubicin may be effective in the treatment of these tumours and significantly prolong patients’ lifespan.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests: None.

  • Patient consent: Patient/guardian consent was obtained for publication.